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OBJECTIVES: Statins are used in primary and secondary pre-
vention of cardiovascular diseases. The goal of this study was to
analyze the outcome of the introduction of generic forms of
statins on the reimbursement drug list paid by the Croatian
Health Insurance Institute (CHII) and the effects of corrections of
the reference prices of this drug group for the ﬁve-year period in
the relation to the ﬁnancial expenditure. METHODS: The data
was obtained from the CHII, which maintains records regarding
drugs issued by Croatian pharmacies. For the investigated period
from 2003 to 2007, annual volumes of prescribed statins were
presented in deﬁned daily doses (DDD) and the expense is pre-
sented in Euros (€). An average cost per DDD was calculated for
each drug of the group. RESULTS: During the ﬁve-year period
from 2003 to 2007, the volume of prescribed group of statins
increased 163% (from 33,294.052 to 87,616.126 DDD) while
the share of branded drugs decreased signiﬁcantly (from 77.02%
to 38.62%). The related expense showed an increase by 18%.
The average cost per DDD dropped for 52% (from €0.69/DDD
in 2003 to €0.33/DDD in 2007). Simvastatin and atorvastatin
were the two most often prescribed statins representing more
than 90% of total expense. The cost per DDD for simvastatin fell
for 58% (from 0.65 to €0.27/DDD). The cost per DDD for
atorvastatin fell 53% (from 0.68 to €0.32/DDD). CONCLU-
SIONS: During the period 2003–2007, the whole group of
statins showed a continuous increase in prescribed DDD. The
average cost per DDD gradually declined after the introduction
of generic substitutions to the reimbursement drug list which
resulted in lowering reference prices accordingly. Therefore the
overall growth of ﬁnancial expenditure was slowed down con-
siderably. For the entire period simvastatin and atorvastatin
remained the most prescribed statins.
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OBJECTIVES: To assess the degree to which methods and
recommendations converge in health technology assessments
of drug eluting stents after the 2006 alert on DES safety.
METHODS: A detailed comparative analysis of HTAs of DES,
conducted by the National Institute for Health and Clinical
Excellence, Ludwig Boltzmann Institute, Kenniscentrum voor de
Gezondheidszorg and the Programs for Assessment of Technol-
ogy in Health was assessed to investigate the ﬁndings and the
convergence or divergence in evidence considered, methods of
assessment and recommendations. RESULTS: The clinical evi-
dence was obtained from randomised controlled trials (RCTs),
non-RCTs, meta-analyses and registry data for the assessments.
A total of 33 RCTs were identiﬁed in all assessments of which
thirteen appeared across more than one assessment and seven
were found across all assessments. The common endpoints
included mortality, myocardial infarction, target lesion revascu-
larisation (TLR), target vessel revascularisation (TVR) and stent
thrombosis. The trial data showed no overall risk of stent throm-
bosis in DES except for one agency that considered the BASKET
late trial. Registry data was used by three of the agencies, which
identiﬁed 35 studies. Of these studies, six were included across
more than one assessment and one in all assessments. All analy-
ses found that DES statistically improved the rates of TLR and
TVR. The registry data for each country were used to populate
the economic models and data from meta-analyses were used to
adjust the relative risk reduction of using DES in patients requir-
ing repeat procedures. The agencies considered a variety of
patient groups. These differences may explain some of the varia-
tion in cost effectiveness results. CONCLUSIONS: The processes
and methods used were broadly similar across the agencies.
However, the information used for the economic models was
based on country speciﬁc registry data. The different data sources
may explain some of the variation in reimbursement decisions.
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OBJECTIVES: Physicians faced with the challenge of syncope
diagnosis usually depend on a series of repeated tests to identify
the cause of syncope or transient loss of consciousness (T-LOC)
events. In addition to ECGs, Tilt Tests, EP Studies and Holter
Monitors, physicians now have the option to also include
implantable loop recorders (ILRs) in their diagnostic pathway.
Given the high burden of syncope diagnostics on hospital
resources, there is increasing attention on the use of ILRs given
their higher diagnostic capabilities and potential to decrease the
burden of multiple and repeated tests. We sought to examine the
potential cost-effectiveness of adding an ILR to the traditional
clinical pathway. We developed a decision-analytic model, com-
paring the cost per diagnosis of standard diagnostics with that of
standard diagnosis plus the ILR. METHODS: Decision-Analytic
Model in Microsoft Excel; Literature Reviews for diagnostic
yields of ECGs, Holter Monitors, Cardiac Ultrasounds, Tilt
Tests, EP Studies and Standard Evaluations; Cost Data based on
Prislista Södra Regionvårdsnämnden, Lund, Sweden. RESULTS:
The ILR-base strategy was observed to signiﬁcantly increase the
rate of diagnosis in an unselected population with recurrent
syncope: 33% of patients receiving an ECG-conﬁrmed diagnosis
compared to 4% in the conventional care group. There was also
a signiﬁcant decrease in the rates of hospitalisation and investi-
gation in patients receiving the ILR. The total cost of testing per
patient in the ILR-based pathway was higher than that in the
conventional pathway, however the cost per diagnosis achieved
was lower in the ILR pathway given the signiﬁcantly higher
diagnostic power of the implanted device. The incremental cost
per correct diagnosis was 12,930 SEK. This ﬁgure accounts for
the differences in total costs and diagnostic efﬁcacy between the
ILR-based and conventional pathways. Results form probabalis-
tic sensitivity analysis suggest a 95% upper bound of 35,305 SEK
and a lower bound dominated by the ILR-based strategy. Simu-
lations across the cost-effectiveness plane suggest an approxi-
mately 7% probability that the ILR-based strategy is both more
effective and less costly. CONCLUSIONS: ILRs have been shown
to exhibit diagnostic superiority when compared to conventional
testing. In this analysis, we observe lower cost per correct
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diagnosis and an acceptable incremental cost per diagnosis when
compared to typical costs of syncope hospitalizations in Sweden.
ILRs are a cost-effective means of achieving a diagnosis in
patients suffering from recurrent unexplained syncope. Further
work could incorporate HRQoL beneﬁts because of reduced
time-to-diagnosis and faster access to treatment. Faster access to
care may also demonstrate cost-savings by preventing death, falls
and fractures while patients remain without treatment.
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OBJECTIVES: To combine clinical results of Endevor® clinical
trials and the associated costs of its use in patients with de novo
lesions of the coronary arteries. METHODS: An economic
model of ENDEAVOR® was constructed based on a retrospective
cost-effectiveness analysis. The basic data of the model were
taken from the literature and expert opinion, and reﬂect the
clinical and economic consequences of the management of new
coronary lesions within the context of the Spanish National
Health System. Expert opinion was obtained from semi
structured interviews and panel consensus from interventional
cardiologists working in seven different Spanish Regions (Auto-
nomias). Only local costs were included, and a discount of 3.5%
was applied to the future costs and outcomes. Probabilistic Sen-
sitivity Analysis) PSA, was performed to evaluate robustness of
our results. RESULTS: Endeavor® had higher total costs than the
bare metal stent and the costs per Target Lesion Revasculariza-
tion avoided with Endeavor® was €6851 (per year) and €10,831
(5 years). In terms of costs per Major Adverse Cardiac Event
avoided with Endeavor®, the results were €7003, €8362 and
€11,322, respectively at year 1, 2 and 5, and the costs per QALY
gained was €132,877, €34,229 and €10,505 at year 1, 2, and 5
years, respectively.The budgetary impact of the progressive intro-
duction of Endeavor® would be practically null, representing
0.4% on the total costs of percutaneous coronary interventions
at 5 years. CONCLUSIONS: The use of the Endeavor® stent
compared to the Bare metal stent and Coronary artery bypass
graft represents an efﬁcient use of resources in coronary artery
disease patients, with cost-effectiveness results below the thresh-
old of efﬁciency deﬁned in Spain. Further real life prospective
data related QoL and health care resources utilization may
improve model accuracy.
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OBJECTIVES: To describe treatment patterns of Glycoprotein
Inhibitors (GPI) and clopidogrel in patients presenting with acute
coronary syndrome (ACS). METHODS: A prospective observa-
tional registry in 3 countries, recruited ACS patients undergoing
percutaneous coronary intervention (PCI), January–August
2007, capturing practice patterns, resource use and quality of
life. RESULTS: A total of 1525 ACS pts (Spain-538, UK-504,
France-483), mean age 62 (SD 12), mean wt 80 kg (SD 15), 22%
female were recruited. Index diagnosis: unstable angina (UA)
and non ST-elevation myocardial infarction (NSTEMI) 62%;
ST-elevation myocardial infarction (STEMI) 38%. Ninety-ﬁve
percent of patients were treated with clopidogrel, whereas 34%
of patients received GPIs (abciximab-21%; eptiﬁbatide-3%);
tiroﬁban-11%) before, during or after PCI. The overall use of
GPIs was balanced between the three countries (Spain-35%,
UK-33%, France-36%). Abciximab was the most frequently
used GPI and was administered mainly in the catherisation labo-
ratory (76%) at the time of PCI. The small molecule GPIs were
more commonly administered before PCI (eptiﬁbatide-55%;
tiroﬁban-78%) and to a lesser extent in the catherisation labo-
ratory (eptiﬁbatide-42%; tiroﬁban-19%). Of the patients who
received abciximab, 60% were STEMI, 26% NSTEMI, and 13%
UA. Administration of abciximab before PCI was more frequent
in STEMI patients (23%) than in UA (5%) and NSTEMI patients
(9%). CONCLUSIONS: Of the 34% of ACS patients receiving a
GPI, abciximab was the most frequently used and was predomi-
nantly administered in the catherisation laboratory, whereas the
other GPIs were more often initiated before. This ﬁts with the
NSTE-ACS guidelines recommendation of the European Society
of Cardiology (ESC). In the STEMI abciximab cohort, an
increase in pre-treatment could be observed.
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OBJECTIVES: Despite statins are accepted as standard for reduc-
ing CHD risk by ~30% via their inﬂuence on LDL-Cholesterol
level, they do not prevent the majority of clinical events like MI,
coronary death or stroke. In addition to other modiﬁable risk
factors like hypertension or diabetes, persistent dyslipidemia,
expressed as LDL-C above target and/or low HDL-Cholesterol
(HDL-C) or high triglycerides (TG), is likely to play a major
causative role in the residual risk of cardiovascular (cv) events
in statin treated patient. As little recent information is available
on the prevalence of persistent dyslipidemia in statin treated out-
patients, this cross sectional survey will diminish this gap.
METHODS: As part of a paneuropean study, 1255 patients in
Germany pretreated with a statin for at least 3 months (45.4%
with diabetes, 14.2% smoker) were included in the period of April
and May 2008. Their cv risk proﬁle was documented and modi-
ﬁable risk factors were compared with current guidelines.
RESULTS: A total of 39.9% of patients had LDL-C levels below
100 mg/ml (median 106.7 mg/dl), 71.4% had HDL-C levels
above 40 (males)/50 (females) mg/dl (median 51 mg/dl), 66.5%
withTGbelow150 mg/dl (median 140,0 mg/dl). A total of 19.1%
of patients had all 3 lipid values within the mentioned ranges.
A total of 39.8% had blood pressure (RR) above 140/90 mmHg,
12.8% of patients had RR values below 140/90 mmHg and lipid
levels within the desired ranges. BMI was 28.1 kg/m2. CONCLU-
SIONS: Since 2000, comprehensive lipid management and treat-
ment of modiﬁable risk factors in Germany has improved over
time but remains still suboptimal and deserves further attention,
which is similar to a prior report from German hospitals.
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